Arimoclomol, formerly known as BRX-220, is a heat shock protein amplifier, and is potentially useful for the treatment of Niemann-Pick disease type C (NP-C). Arimoclomol is thought to work by inducing molecular chaperones to activate a regular cellular protein repair pathway. Many diseases could be treated with rimoclomol. It is arimoclomol that initiates the HPR. It is thought to function at Hsp70.
Physicochemical Properties
| Molecular Formula | C18H24CLN3O7 |
| Molecular Weight | 429.85206 |
| Exact Mass | 429.13 |
| Elemental Analysis | C, 50.30; H, 5.63; Cl, 8.25; N, 9.78; O, 26.05 |
| CAS # | 289893-26-1 |
| Related CAS # | Arimoclomol;289893-25-0;Arimoclomol citrate;368860-21-3 |
| PubChem CID | 72941795 |
| Appearance | White to off-white solid powder |
| LogP | 1.528 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 29 |
| Complexity | 456 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | Cl/C(C(C=CC=1)=CN1=O)=N\OC[C@H](O)CN2CCCCC2.OC(/C=C\C(O)=O)=O |
| InChi Key | OHUSJUJCPWMZKR-GARNONDBSA-N |
| InChi Code | InChI=1S/C14H20ClN3O3.C4H4O4/c15-14(12-5-4-8-18(20)9-12)16-21-11-13(19)10-17-6-2-1-3-7-17;5-3(6)1-2-4(7)8/h4-5,8-9,13,19H,1-3,6-7,10-11H2;1-2H,(H,5,6)(H,7,8)/b16-14-;2-1-/t13-;/m1./s1 |
| Chemical Name | Z)-but-2-enedioic acid;(3Z)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride |
| Synonyms | Arimoclomol maleate; BRX220; BRX-220; BRX 220; BRX-345; BRX345; BRX 345 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HSP |
| ln Vivo | Arimoclomolmaleate (BRX-220; side wall; 5d; 20 mg/kg) guards against acute pancreatitis brought on by cholecystokinin octapeptide (CCK) [1]. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats, body weight 240 to 270g [1] Doses: 20 mg/kg Route of Administration: intragastric (po) (po)administration for 5 days Experimental Results: Protective effect on CCK-induced acute pancreatitis. |
| References |
[1]. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32(12):1283-92. [2]. Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96. |
Solubility Data
| Solubility (In Vitro) |
DMSO: ~250 mg/mL (~581.6 mM) H2O: ~100 mg/mL (~232.6 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 100 mg/mL (232.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3264 mL | 11.6320 mL | 23.2639 mL | |
| 5 mM | 0.4653 mL | 2.3264 mL | 4.6528 mL | |
| 10 mM | 0.2326 mL | 1.1632 mL | 2.3264 mL |